About Synthorx
Synthorx is a Healthcare company based in San Diego (United States) founded in 2014, and was acquired by Sanofi in December 2019. Provider of solutions for drug discovery, diagnostics, and vaccines using a synthetic DNA base pair. Synthorx has raised $79 million across 3 funding rounds from investors including Sanofi, Orbimed and RA Capital. The company has 50 employees. Its focus areas include Life Sciences, Genomics, Applied Genomics and Synthetic Biology. Its legal entity is SYNTHORX, INC. Its competitors include Amyris, AskBio and Ginkgo Bioworks; 3 of its 3 listed competitors have raised funding.
Company details
Synthorx was founded in 2014 in San Diego, United States, within the biotechnology sector. Solutions for drug discovery, diagnostics, and vaccine development are offered through the use of synthetic DNA base pairs that expand the genetic alphabet. Several unnatural bases have been synthesized for in vitro applications, with PCR amplification achieved at standard efficiency and fidelity. A base transporter protein is required for cellular uptake of these bases.
- Headquarters San Diego, United States
- Employees 50
- Stage Acquired
- SectorsHealthcare
- Website synthorx.com
- Social LinkedIn X Facebook
- Acquired by Sanofi (Dec 2019)
- Legal Name Synthorx, Inc
Funding Insights of Synthorx
Synthorx has successfully raised a total of $79M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $63 million completed in April 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $79M
- Total Rounds 3
- Last Round Series C — $63M
- First Round $6M
(Jun 2014)
- Investors Count 6
All 3 funding rounds of Synthorx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2018 | $63M | Series C | – | Orbimed | |
| Jul 2016 | $10M | Series B | – | RA Capital Management | |
| Jun 2014 | $6M | Series A | – | Avalon Ventures, Correlation Ventures | – |
7 investors in total: 7 institutional.
Investors in Synthorx
Synthorx has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Sanofi, Orbimed and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Seed and early-stage venture capital is provided to US companies. | avalon-ventures.com | Cambridge, United States | ||
Venture capital firm focused on aerospace, biopharma, consumer, and multiple sectors | correlationvc.com | San Francisco, United States | ||
Early-stage life science focused VC firm investing in geographies such as Europe and the US | medicxi.com | London, United Kingdom | ||
Early- to growth-stage startups are targeted for venture capital investments. | oup.vc | Bala Cynwyd, United States | ||
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
Pharmaceutical and nutraceutical products are developed across seven therapeutic areas. | 1973 | sanofi.com | Paris, France |
Investor details for Synthorx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Synthorx
4 dated milestones of Synthorx across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Synthorx is founded.
- Funding First funding round of $6.0M.
- Funding Latest funding round, Series C, of $63.0M.
- Exit Acquired by Sanofi.
Competitors of Synthorx
Synthorx has 3 listed competitors in our database, 3 of them funded. They include Amyris, AskBio and Ginkgo Bioworks.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| amyris.com | 2003 | Emeryville, United States | $487.2M | 747 | Developer of renewable products for industrial solutions | |
| askbio.com | 2001 | Durham, United States | $235M | Gene and protein therapies are developed for treating various diseases. | ||
| ginkgobioworks.com | 2008 | Boston, United States | $795.75M | 1,218 | Gene editing-based cultured ingredients are provided for agriculture. |
Detailed competitors of Synthorx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Synthorx
Websites that share an audience with Synthorx (synthorx.com).
Websites whose visitors overlap most with Synthorx. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| biopharmguy.com | 100% | #377,294 | View details |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Synthorx (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Synthorx
Complete news archive for Synthorx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Synthorx
Synthorx was founded in 2014.
Synthorx is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Synthorx is a funded company, having raised a total of $79M across 3 funding rounds to date. The company's 1st funding round was a Series A of $6M, raised on Jun 2014.
Synthorx has 50 employees.
Synthorx was founded in 2014 in San Diego, United States, within the biotechnology sector. Solutions for drug discovery, diagnostics, and vaccine development are offered through the use of synthetic DNA base pairs that expand the genetic alphabet. Several unnatural bases have been synthesized for in vitro applications, with PCR amplification achieved at standard efficiency and fidelity. A base transporter protein is required for cellular uptake of these bases.
Synthorx's top competitors include Amyris, AskBio and Ginkgo Bioworks.
Synthorx has 7 investors. Key investors include Sanofi, Orbimed, RA Capital, Avalon Ventures, and Correlation Ventures.
Synthorx operates through Synthorx, Inc.
Yes. Synthorx was acquired by Sanofi in December 2019.